GLP-1 Receptor Agonists: Central Nervous System Research Directions
The genetic pathway enrichment findings (Chapter Genetic and Epigenetic Factors, Section Convergent Brain-Enriched Genetic Architecture in Fibromyalgia and ME/CFS) and the orexin-GLP-1 reciprocal dysregulation hypothesis Ruhrländer, Schieffer, and Schieffer (2026) together motivate CNS-directed research on GLP-1 receptor agonists in ME/CFS. All considerations below are research-stage; no clinical data exist.
No study has measured whether ME/CFS patients have normal endogenous GLP-1 secretion, glucose-dependent insulinotropic polypeptide (GIP), or related incretin responses to a standardised meal. This is the most basic unresolved question. If GLP-1 secretion is blunted — due to dysbiosis, vagal dysfunction, or L-cell mitochondrial impairment — then GLP-1 RAs would function as hormone replacement. If secretion is normal, the genetic pathway enrichment reflects receptor-level or downstream pathway involvement, and GLP-1 RAs act supraphysiologically. A simple meal tolerance test with serial GLP-1, GIP, glucose, insulin, and C-peptide measurements (0, 15, 30, 60, 90, 120 min) would answer this question.
Prediction: Blunted GLP-1 AUC in ME/CFS vs BMI-matched controls during mixed meal tolerance test. GLP-1 AUC correlates negatively with fatigue severity and positively with vagal tone (HRV high-frequency power). Null result: no difference, falsifying the deficiency hypothesis.
Status: Standard endocrine assay; zero ME/CFS data. Estimated cost: USD 200–300 per patient.
Certainty: 0.25. (0.20→0.25: convergence with Central NE Deficiency — GLP-1 incretin resistance and catecholamine deficiency both predict cerebral energy homeostasis failure via complementary pathways from different physiological systems.)
GLP-1 receptors on neurons and glia regulate cerebral glucose uptake, mitochondrial biogenesis, and insulin sensitivity. If ME/CFS involves central GLP-1 resistance — analogous to the well-documented central insulin resistance in Alzheimer’s disease (“Type 3 diabetes”) — neurons would be metabolically starved despite normal or elevated blood glucose. This could explain the reduced cerebral glucose metabolism observed in some ME/CFS PET studies and the subjective experience of “brain fog” as “brain not getting enough fuel.” GLP-1 RAs at supraphysiological doses might overcome resistance, improving neuronal energy availability independent of peripheral effects (Athauda et al. 2026).
Testable prediction: Acute IV GLP-1 (7-36) infusion in ME/CFS should show blunted cerebral FDG uptake response compared to healthy controls (FDG-PET). Chronic GLP-1 RA treatment should increase resting cerebral glucose metabolism in frontal cortex.
Status: Entirely inferential. No central GLP-1 sensitivity measurements exist in any disease.
Certainty: 0.25. (0.20→0.25: convergence with State-Dependent Endothelial Dysfunction — glycocalyx shedding in T2D microvascular literature and state-dependent ED in ME/CFS physiology point to same state-dependent endothelial failure from complementary domains.)
Endothelial dysfunction in ME/CFS (Chapter Cardiovascular Dysfunction) includes glycocalyx degradation, impaired flow-mediated dilation, and microvascular permeability. GLP-1 receptors on endothelial cells activate eNOS, increase NO bioavailability, and preserve glycocalyx integrity. By stabilising the glycocalyx, GLP-1 RAs could reduce exercise-induced microvascular leakage and immune cell extravasation into muscle tissue — mechanically interrupting the cascade that leads to PEM. Exercise-induced glycocalyx shedding is a normal physiological response that resolves within hours; pathological persistence occurs in endothelial dysfunction and parallels the 24–48h delayed worsening characteristic of PEM.
Testable prediction: ME/CFS patients should show elevated serum glycocalyx degradation products (syndecan-1, hyaluronan) at 48h post-CPET compared to sedentary controls. A 4-week course of liraglutide should reduce post-exercise glycocalyx shedding and correlate with reduced PEM severity.
Status: No glycocalyx study in ME/CFS. GLP-1 RA glycocalyx protection established in T2D (meta-analytic).
Certainty: 0.35. (0.30→0.35: convergence — GLP-1 RA NK enhancement from T2D pharmacology and clinical evidence of corticosteroid NK suppression both indicate NK function is pharmacologically modifiable, via complementary evidence from different domains.)
NK cell dysfunction is one of the most replicated immune findings in ME/CFS (Chapter Immune System Dysfunction). GLP-1 receptors are expressed on NK cells and their activation enhances cytotoxicity in T2D (Deng, Chen, and Shi 2025). No study has examined GLP-1 RA effects on ME/CFS NK cells. Ex vivo exposure of ME/CFS PBMCs to GLP-1 RA (liraglutide, semaglutide) would provide the first human ME/CFS-specific mechanistic data with zero patient drug exposure.
Testable prediction: ME/CFS PBMC NK cells exposed to GLP-1 RA (1–100 nM) should show dose-dependent increase in K562 target cell killing vs vehicle. Effect size correlates with baseline NK dysfunction severity. Null: no effect, narrowing the immune pathways potentially responsible for any clinical benefit.
Status: Feasible with small blood volumes; ex vivo design eliminates tolerability concerns; zero ME/CFS data.
1 Research Priorities and Cross-Disease Bridges
The major barrier to GLP-1 RA neuroprotection is blood-brain barrier penetration. Most GLP-1 RAs reach CNS primarily through circumventricular organs and vagal afferents — limited and variable access. Intranasal delivery bypasses the BBB and delivers GLP-1 directly to the brain via olfactory and trigeminal pathways, achieving high CNS concentrations with minimal systemic exposure. This could target neuroinflammation, cerebral glucose metabolism, and orexin-system modulation without GI adverse effects, weight loss, or cost of systemic GLP-1 RAs. Intranasal insulin is under investigation in Alzheimer’s disease. Intranasal GLP-1 has shown CNS effects in healthy volunteers (reduced appetite, altered fMRI brain activity). No intranasal GLP-1 study in any disease has progressed past Phase 1.
Status: Technically feasible but unvalidated. Formulation stability and safety in ME/CFS entirely unknown. Falsifiability: intranasal GLP-1 achieves ≤2× CSF-to-plasma ratio vs subcutaneous route → CNS-targeted delivery advantage is negligible, falsifying the route-specific hypothesis.
If central GLP-1 resistance is present in ME/CFS, measuring the acute cerebral metabolic response to IV GLP-1 (7-36) infusion by FDG-PET could provide a direct CNS GLP-1 sensitivity readout. Healthy brains show increased FDG uptake in prefrontal cortex and hypothalamus after GLP-1 infusion. Blunted FDG response would indicate central GLP-1 resistance, suggesting need for higher doses or CNS-penetrant compounds. The cost (approximately USD 3,000–5,000) and radiation exposure limit scalability to proof-of-concept studies.
Status: GLP-1 FDG-PET response documented in small healthy/T2D studies (n=10–20). No ME/CFS infusion study exists. CNS resistance not established. Falsifiability: acute IV GLP-1 at the highest safe dose produces no significant increase in prefrontal FDG uptake vs saline in ME/CFS → falsifies central GLP-1 sensitivity as a measurable phenomenon.
A single biomarker will never capture the full GLP-1 pathway. An integrative score combining four cheap, accessible measures could classify patients by pathway integrity: (1) postprandial GLP-1 AUC (meal tolerance test), (2) fasting DPP-4 activity (serum fluorogenic assay), (3) HRV high-frequency power (vagal tone, 5-min recording), and (4) faecal butyrate producers (qPCR for Faecalibacterium prausnitzii, Roseburia). Each component independently reflects GLP-1 pathway function (secretion, degradation, neural sensitivity, nutritional input). Combined into a weighted score (e.g., PCA-derived), it would identify patients with “multi-level GLP-1 pathway failure” vs isolated defects. No integrative GLP-1 score exists in any disease.
Status: Components individually validated; integrative approach novel; validation requires treatment outcome data. Falsifiability: score predicts GLP-1 RA treatment response with AUC ≤0.55 → individual components mis-classify individually and in combination, score offers no predictive value over chance.
Gardner 2026 reports protective ME/CFS alleles overlap with T2D protection. This creates a testable prediction: GLP-1 RA effects in ME/CFS may occur through the same pathways that protect against T2D, which are distinct from glucose lowering — specifically, anti-inflammatory (NF-kB, CRP), endothelial (eNOS, glycocalyx), and mitochondrial (PGC-1α, biogenesis) effects (Ren et al. 2025) (Athauda et al. 2026). If true, GLP-1 RAs could benefit normal-weight, normoglycaemic ME/CFS patients as much as pre-diabetic ones, and baseline HbA1c would not predict symptom response. This would substantially expand the eligible population for any future trial.
Testable prediction: In a GLP-1 RA ME/CFS trial, baseline HbA1c will NOT predict symptom response. CRP reduction and symptom improvement will correlate, but neither will correlate with HbA1c change. Falsified if only pre-diabetic ME/CFS patients respond.
Status: Glucose-independence of GLP-1 RA anti-inflammatory effects established in T2D. Protective allele overlap new. No normoglycaemic ME/CFS data.
Standardised mixed meal tolerance test with serial GLP-1, GIP, PYY, and glucose measurements (0, 15, 30, 60, 90, 120 min) could stratify patients into low/normal/high GLP-1 responders. Patients with low GLP-1 AUC are predicted to benefit most from GLP-1 RAs (replacement rationale). Those with normal/high GLP-1 AUC may benefit more from DPP-4 inhibitors (which raise already-adequate GLP-1) or may be GLP-1 RA non-responders. This biomarker would enrich a trial for predicted responders, reducing sample size requirements.
Testable prediction: In a GLP-1 RA trial, baseline GLP-1 AUC tertile significantly predicts treatment response. Lowest tertile shows ≥2× the effect size of highest tertile for PEM improvement. Falsified if response is uniform across tertiles.
Status: Standard endocrine assay; GLP-1 AUC variability 2–3× between healthy individuals; zero ME/CFS data.
Serum DPP-4 activity can be measured by a simple fluorogenic substrate assay (approximately USD 20/sample). Elevated DPP-4 predicts rapid GLP-1 degradation. Patients with high DPP-4 activity may benefit more from DPP-4 inhibitors (blocking degradation) than from GLP-1 RAs (which are DPP-4-resistant but still rely on endogenous GLP-1 production for vagal afferent effects). Patients with low DPP-4 activity may be GLP-1 analogue-responsive regardless. This biomarker stratifies the choice between two drug classes — DPP-4 inhibitors (cheap, oral, well-tolerated) vs GLP-1 RAs (injectable, costly, less well-tolerated) — based on individual biology, not assumption.
Testable prediction: In a crossover trial of sitagliptin vs liraglutide, baseline DPP-4 activity predicts the better-tolerated and more-effective drug at an individual level. High DPP-4 → sitagliptin response; low DPP-4 → liraglutide response.
Status: DPP-4 activity varies 3× between individuals, genetically regulated, modifiable by inflammation. Zero ME/CFS data. DPP-4→treatment selection untested in any disease.
GLP-1 exerts many CNS effects through vagal afferents (NTS → hypothalamus pathway), not direct BBB penetration. Vagal tone is reduced in ME/CFS (HRV evidence), which would blunt the sensitivity of the vagal GLP-1 signalling pathway even if GLP-1 levels are normal. Auricular transcutaneous vagal nerve stimulation (tVNS) activates vagal afferents directly, potentially restoring the sensitivity of the GLP-1→vagal→CNS axis. This would enhance the effect of endogenous GLP-1 without changing GLP-1 levels. tVNS is non-invasive, safe, and self-administered at home.
Testable prediction: 20 min daily auricular tVNS × 8 weeks increases postprandial vagal HRV response (high-frequency power) and subjective energy (VAS) after a standardised meal vs sham stimulation. Null: tVNS improves HRV but does not alter GLP-1-related outcomes, confirming vagal dysfunction but suggesting vagal and GLP-1 pathologies are dissociable.
Status: Vagal GLP-1 pathway well-characterised in preclinical models. tVNS RCTs show benefit in pain, inflammation. No tVNS × GLP-1 combination study exists.
Endogenous GLP-1 is released from intestinal L-cells in response to nutrients. L-cells express mechanosensors (PIEZO2, TRPA1) and chemosensors (FFAR2/3 for SCFAs). The gut → vagus → NTS → hypothalamus circuit is the major physiological route for GLP-1 signalling, independent of BBB penetration. In ME/CFS, dysbiosis (reduced SCFAs, altered bile acids), slow gut motility, and vagal dysfunction may collectively suppress endogenous GLP-1 release, creating a vicious cycle: low GLP-1 → reduced vagal tone → gut dysmotility → further GLP-1 suppression. This cycle could be interrupted by prokinetics, prebiotics, or vagal nerve stimulation — entirely without pharmacological GLP-1 RAs. The orexin-GLP-1 reciprocal regulatory cycle described by Ruhrländer 2026 is positioned within this broader gut-brain axis Ruhrländer, Schieffer, and Schieffer (2026).
Testable prediction: ME/CFS patients show blunted postprandial GLP-1 response to a mixed meal vs controls. Baseline GLP-1 correlates with α-diversity and SCFA (butyrate) levels. Vagal tone (HRV high-frequency power) predicts GLP-1 response amplitude. Restoring SCFA levels (prebiotics, butyrate) increases GLP-1 AUC.
Status: Each link individually plausible. Integrated cycle entirely hypothetical. ME/CFS GLP-1 secretion dynamics unmeasured.
GIP receptors are also expressed in the brain, and GIP-GLP-1 co-agonism (tirzepatide) shows synergistic metabolic effects. However, Forny Germano 2024 found tirzepatide ineffective in Alzheimer’s mice — the same negative result as semaglutide — suggesting that dual agonism alone is insufficient without CNS penetrance (Forny Germano et al. 2024). The practical question: does combined incretin agonism cover a broader range of PrecisionLife-identified ME/CFS genes than GLP-1 alone? This is answerable computationally by intersecting the ME/CFS risk gene set with GLP-1R, GIPR, and GCGR target pathways. If GIPR/GCGR targets add no significant coverage beyond GLP-1R alone, dual agonism offers no genetic advantage.
Testable prediction: GIPR and GCGR target pathways do NOT add significant additional ME/CFS gene coverage beyond GLP-1R targets. Falsified if dual agonism significantly expands pathway coverage.
Status: Computational analysis feasible now without any patient data. Vear 2025 Nature Metabolism reviews dual/triple agonists. No ME/CFS-specific compound data.
PrecisionLife is developing combinatorial genetic classifiers to predict GLP-1 RA response. An intermediate validation step before any ME/CFS patient exposure: retrodict GLP-1 RA efficacy using the ME/CFS-derived classifier in existing T2D/obesity GLP-1 RA trials (EXSCEL, REWIND, LEADER), where genotype and outcome data exist. If the ME/CFS-derived classifier predicts GLP-1 RA response in non-ME/CFS populations, it cross-validates the genetic pathway enrichment framework without requiring an ME/CFS trial. This could raise the certainty of the PrecisionLife findings from 0.45 (conference presentation) to ~0.60 (independent validation).
Testable prediction: The classifier predicts HbA1c response in existing T2D GLP-1 RA trial cohorts. Falsified if no cross-cohort prediction is achieved.
Status: Requires access to existing GLP-1 RA trial genotype data. No such analysis has been reported. Fast, cheap derisking step.
No pharmacological intervention has been shown to prevent or reduce PEM. Since PEM involves delayed (24–72h) worsening after exertion, a substudy embedded in a trial would use standardised CPET provocation at baseline and end-of-treatment, with serial symptom and biomarker measurement at 0, 24, 48, 72h. The hypothesis: GLP-1 RA pre-treatment reduces the AUC of PEM symptoms and post-exertional inflammatory markers (IL-6, CRP) compared to placebo. This directly tests whether GLP-1 RAs modify the defining symptom of ME/CFS.
Testable prediction: GLP-1 RA × 8 weeks reduces CPET PEM symptom AUC ≥30% vs placebo, with parallel reduction in post-CPET IL-6 spike at 24h. Null: no effect on PEM timeline despite improved baseline symptoms, suggesting GLP-1 RA mechanism is independent of PEM generation.
Status: PEM provocation is ME/CFS-specific methodology. No prior GLP-1 RA PEM provocation study. Unclear whether single-dose or chronic dosing needed.
Qi et al. 2024 (Nature Metabolism) demonstrated that Desulfovibrio-produced H2S suppresses GLP-1 secretion from L cells by inhibiting mitochondrial function (Qi et al. 2024). Bismuth subsalicylate chelates luminal H2S, rescuing GLP-1 production in mice. ME/CFS patients have altered gut microbiota including potential increases in H2S producers. BSS is an OTC, cheap, well-tolerated, oral medication with >50 years of safety data. This provides a mechanism to increase endogenous GLP-1 without injected drugs.
Testable prediction: BSS 524 mg QID × 2 weeks increases postprandial GLP-1 AUC by ≥50% in ME/CFS vs placebo. GLP-1 increase correlates with reduction in breath H2S. Null: no GLP-1 change, suggesting H2S-mediated GLP-1 suppression is not relevant in ME/CFS.
Status: Compelling mouse model; OTC human safety established; zero human GLP-1 data with BSS in any condition.
Palmitoylethanolamide (PEA) activates PPAR-α, which upregulates GLP-1 receptor expression in the brain. By increasing GLP-1R density, PEA could enhance the response to both endogenous and exogenous GLP-1 without increasing GLP-1 levels — a “sensitivity enhancer” approach distinct from secretagogues or receptor agonists. PEA is OTC, safe, with positive RCT data in fibromyalgia and chronic pain. PEA also reduces mast cell activation (relevant to ME/CFS-MCAS). No study has examined PEA × GLP-1 axis interaction.
Testable prediction: PEA 600mg BID × 8 weeks increases CSF GLP-1R expression (surrogate) and enhances GLP-1 response to a mixed meal (higher peak, longer duration) in ME/CFS vs placebo.
Status: PEA safety established; GLP-1R upregulation mechanism is preclinical; combination effect entirely unexamined.
The orexin↔︎GLP-1 reciprocal disruption described by Ruhrländer Ruhrländer, Schieffer, and Schieffer (2026) suggests that neither pathway alone can be re-normalised without addressing its partner. A triple-intervention protocol simultaneously targeting GLP-1 (dietary/protein-first), glymphatic clearance (lateral sleep positioning, sleep hygiene), and orexin stabilisation (morning light exposure, circadian meal timing) could break the self-reinforcing cycle. Each intervention alone may be insufficient; combination may produce synergy.
Testable prediction: A 4-week triple protocol (morning protein-first meal + lateral sleep + 30 min morning bright light) improves DSQ-PEM by ≥40% vs a single intervention (protein-first alone). Triple synergy indicated by disproportionate improvement vs additive individual effects.
Status: Entirely hypothetical. No triple circuit study exists. Adherence burden may be high. Each component is zero-cost and zero-risk.
Severe/very-severe patients cannot access injectable GLP-1 RAs (cost, tolerance, refrigeration, travel). Even oral drugs may be problematic (swallowing difficulty, GI sensitivity). An adapted approach: (a) sublingual berberine (bypasses GI, avoids nausea), (b) liquid whey protein for GLP-1 stimulation (easier than solids), (c) chronobiotic meal timing within the patient’s achievable schedule, (d) transdermal magnesium (supports GLP-1 secretion via calcium-dependent pathways). Focus entirely on endogenous GLP-1 enhancement — no exogenous drug. This addresses the population most in need and least served.
Testable prediction: Severe-ME/CFS-adapted protocol (sublingual berberine 200mg + liquid whey protein 20g, both TID) is tolerable (≥80% completion) and shows ≥20% improvement in Bell Disability Scale at 12 weeks.
Status: Severe ME/CFS adaptation is needed regardless. GLP-1 relevance in severe subgroup unknown. Safety profile acceptable for all components individually.
Two human disease models offer potential mirrors of GLP-1 dysregulation relevant to ME/CFS: (1) Post-gastric-bypass reactive hypoglycaemia, driven by GLP-1 hypersecretion from remodelled gut anatomy — producing autonomic symptoms (palpitations, sweating, tremor, fatigue) that partially overlap ME/CFS. If ME/CFS involves GLP-1 deficiency (rather than excess), the symptom profile should be the inverse. (2) Anorexia nervosa, involving chronic caloric restriction, reduced GLP-1 secretion, fatigue, and bradycardia. Unlike AN, where refeeding restores GLP-1, ME/CFS GLP-1 deficiency (if present) may be calorie-independent (L-cell dysfunction, vagal dysregulation, DPP-4 elevation). Comparing meal-challenge GLP-1 dynamics across post-bypass, AN, and ME/CFS would test whether GLP-1 pathophysiology is relevant to ME/CFS symptom generation and whether the deficiency is primary or secondary to low intake.
Testable prediction: ME/CFS patients have lower GLP-1 AUC than BMI-matched controls and comparable GLP-1 to AN patients — but unlike AN, GLP-1 does NOT normalise after 4 weeks of caloric normalisation. Post-bypass patients do not report ME/CFS-like PEM.
Status: Post-bypass and AN GLP-1 data are well-characterised. ME/CFS GLP-1 data entirely absent. Cross-disease comparison is novel and testable with standard meal challenges.
The existing pathophysiological DAG (Chapter Integrative Models and Multi-System Pathophysiology) lacks a GLP-1 node. Several quantitative extensions are warranted: (1) Endogenous GLP-1 dynamics node — add [Endogenous GLP-1] with input edges from gut SCFA levels, meal protein content, circadian phase, and DPP-4 activity; output edges to orexin stability, cerebral glucose uptake, and systemic inflammation. The GLP-1 node should be modelled with a circadian forcing function (peak AM, trough PM) and a nutrient-input response function. (2) DPP-4/CD26 degradation kinetics — modelled as Michaelis-Menten: d[GLP-1]/dt = secretion_rate(t, nutrients) − (Vmax_DPP4 × [GLP-1])/(Km + [GLP-1]). If DPP-4 activity is elevated in ME/CFS, the Vmax term increases, producing GLP-1 deficiency non-linearly: a 2× DPP-4 increase requires a 3–4× secretion increase to maintain normal GLP-1 levels. (3) GLP-1 RA PKPD model with subgroup-specific parameters — extend existing T2D PKPD models by adding ME/CFS-specific parameters (reduced vagal tone shifts EC50 for CNS effects; reduced cerebral glucose metabolism alters dose-response for cognitive endpoints; baseline inflammation modifies anti-inflammatory dose-response). These extensions would predict that inflammatory-subgroup patients require lower doses for anti-inflammatory effects but higher doses for CNS effects — informing trial design.
Status: GLP-1 dynamics well-quantified in endocrinology. ME/CFS-specific parameters unmeasured. DPP-4 kinetics established (Km ~5 µM for GLP-1). GLP-1 RA PKPD models exist for T2D. All parameterisation requires ME/CFS-specific data. Falsifiability: GLP-1-augmented DAG does NOT improve PEM severity prediction (ΔR² ≤ 0.10) over the current model without GLP-1 node → GLP-1 pathway adds negligible explanatory power.
Measuring GLP-1 requires venipuncture, precise timing (GLP-1 half-life ~2 min with DPP-4), and expensive ELISA kits. Urinary GLP-1 9-36 amide (the primary DPP-4 cleavage product) could provide a non-invasive, integrated measure of GLP-1 secretion over hours. If validated against serum GLP-1 AUC, this would enable repeated home-based measurement — before/after meals, PEM episodes, drug administration — without clinical visits. No validated human urinary GLP-1 assay exists. Technical challenges are significant (peptide degradation, concentration variability). If feasible (r ≥ 0.6 correlation with serum GLP-1 AUC), transformative for at-home GLP-1 monitoring in n-of-1 trials.
Status: Speculative. GLP-1 fragments excreted in urine in rodents. No validated human urinary GLP-1 assay. Technical feasibility uncertain. Falsifiability: urinary GLP-1 9-36/creatinine correlates with serum GLP-1 AUC at r < 0.3 despite optimised collection protocol → the approach is infeasible as a clinical monitoring tool.